Treatment For Baldness May Aid Female Chemotherapy Patients (NAPSA)—There may be good news for females who have experienced hair loss due to chemotherapy. A recent pilot study conducted in Auckland, New Zealand, and published in the peer-reviewed medical journal Psycho-Oncology, indicates that a process used to treat breast cancer patients and those with the condition commonly known as pattern baldness has shown promise in reducing chemotherapy-induced excessive hairloss. It is estimated that androgenetic alopecia—pattern bald- ness—will affect up to 60 percent of men and 30 percent of women during their lifetimes. In women, it is characterized by general thinning with moderate loss at the hairline and crown, and in men, by a receding hairline with moderate or extensive loss at the crown. According to Dr. Timothy Meakin, one ofthe clinical investigators on the New Zealand study, “The loss of hair is one of the most anticipated and unwanted side effects of chemotherapy. Twelve of the 13 female patients in this study had good hair retention during chemotherapy,” Dr. Meakin said. “The women in our study group generally felt more confident about having chemotherapy with the availability of the ETG Treatment. We are also going to use the machine on children suffering from alopecia.” Over the years, medical re- searchers have reported that cer- In a newClinicaltrial, 12 out of 13 female breast cancer patients undergoing chemotherapy had goodhair retention. company that owns the worldwide rights to the ETG device used in the clinical trials, has applied this research to the development of a treatment for common baldness called ETG Treatment. In the past few years, $15 million has been invested in developing ETG as a treatment for androgenetic alopecia. This one-of-a-kind treatmentis presented as a non-drug, non-sur- gical medical option for those seeking a response to continued excessive hair loss. ETG, or ElectroTrichoGenesis, involves the non-invasive stimulation of hair follicles on the scalp by the positive influence of an electrostatic field. This treatment is addressed in the November 10th, 2003 issue of BusinessWeek. In the article, the treatment is outlined and is said to have a promising outlook. A clinical study of the effective- tain electrical frequencies seem to stimulate healing responses in ness of the treatment conducted at the University of British ing soft-tissue repair and bone healing. A company called Current Technology Corporation (OTCBB- matology (July-August 1990), a peer-reviewed medicaljournal. various parts of the body, includ- CRTCF), a Canadian-based Columbia was also published in the International Journal of DerTo learn more, visit the Web site at www.etgtreatment.com.
